ClinicalTrials.gg
CompletedNCT05451329Updated Jan 17, 2024Results posted

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure

A Phase 2 interventional study of VVN539 Ophthalmic Solution 0.02% and VVN539 Ophthalmic Solution 0.04% in Glaucoma, Open-Angle, sponsored by VivaVision Biotech, Inc. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-17.

Sponsored by VivaVision Biotech, Inc · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 348 studies in Glaucoma, Open-Angle with a site in United States — 49 open to participants now, 67 under way, 5 of them phase 3. Glaucoma, Open-Angle · United States.

Enrollment
163rd of 279
68 · median 84
Started
2022
with 12 others
Phase 2
76 of 348
5 open now
Registered
275th of 348
by date

Among the 348 studies in Glaucoma, Open-Angle with a site in United States, this one is the 163rd largest by enrollment of the 279 interventional ones that give a count, is one of 13 that started in 2022, is one of 76 in phase 2, and was the 275th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

49 of the 348 studies in Glaucoma, Open-Angle with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 348 studies in Glaucoma, Open-Angle with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, parallel-comparison, multi-center, double-masked, randomized, vehicle-controlled dose-response study assessing the safety and ocular hypotensive efficacy of VVN539 in subjects with POAG or OHT. Three different dosing regimens (once a day [q.d.] in the morning, q.d. in the evening and twice a day [b.i.d.]) will be tested for 7-9 days, each.

03

Conditions studied

  • Glaucoma, Open-Angle

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older.
  • Diagnosis of primary open-angle glaucoma or ocular hypertension in both eyes that are untreated, or if treated, in the opinion of the investigator are well controlled on 2 or fewer ocular hypotensive medications prior to Visit 1.
  • Unmedicated intraocular pressure of ≥ 22 mm Hg and ≤ 36 mm Hg in the study eye, with no more than 5 mm Hg inter-eye difference at 08:00AM and 10:00AM at Visit 2.
  • Corrected visual acuity in each eye +1.0 or better by Early Treatment Diabetic Retinopathy Scale in each eye (equivalent to Snellen 20/200)

Exclusion criteria

Exclusion Criteria:

  • Known to any kinase inhibitors, any or preservative of the formulation or to topical anesthetics or fluorescein.
  • Unmedicated IOP of > 36 mm Hg in either eye at any time point at Visit 2.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
68 participants (actual)

Study arms

  • Active comparator
    VVN539 Ophthalmic Solution 0.02%

    VVN539 Ophthalmic Solution 0.02%

    Drug: VVN539 Ophthalmic Solution 0.02%

  • Active comparator
    VVN539 Ophthalmic Solution 0.04%

    VVN539 Ophthalmic Solution 0.04%

    Drug: VVN539 Ophthalmic Solution 0.04%

  • Placebo comparator
    VVN539 Ophthalmic Solution Vehicle

    VVN539 Ophthalmic Solution Vehicle

    Drug: VVN539 Ophthalmic Solution Vehicle

Interventions

  • DrugVVN539 Ophthalmic Solution 0.02%

    Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days

  • DrugVVN539 Ophthalmic Solution 0.04%

    Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days

  • DrugVVN539 Ophthalmic Solution Vehicle

    Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days

06

What researchers measure

Primary outcomes

  1. Mean Intraocular Pressure

    mmHg

    Time frame: 8AM, 10AM, and 4PM at Day 7; Day 14 and Day 21

Secondary outcomes

  1. Mean Change in Intraocular Pressure From Baseline

    mmHg

    Time frame: 8AM, 10AM, and 4PM at Day 7; Day 14 and Day 21

07

Results

Posted Jan 17, 2024

Participant flow

Participant flow — Overall Study
MilestoneVVN539 Ophthalmic Solution 0.02%VVN539 Ophthalmic Solution 0.04%VVN539 Ophthalmic Solution Vehicle
Started232223
Completed202023
Not completed320
Withdrew: Adverse event110
Withdrew: Withdrawal by subject100
Withdrew: Investigational product lot exchange110

Outcome measures

PrimaryMean Intraocular Pressure

mmHg

Time frame:
8AM, 10AM, and 4PM at Day 7; Day 14 and Day 21
Reported as:
Mean · mmHg
Mean Intraocular Pressure
mmHgVVN539 Ophthalmic Solution 0.02%VVN539 Ophthalmic Solution 0.04%VVN539 Ophthalmic Solution Vehicle
0800 AM Day 721.8 ± 4.620.5 ± 2.523.4 ± 3.9
1000 AM Day 719.7 ± 4.719.0 ± 2.822.0 ± 3.1
0400 PM Day 719.1 ± 4.118.1 ± 2.621.7 ± 2.9
0800 AM Day 1421.1 ± 5.019.6 ± 3.923.1 ± 3.5
1000 AM Day 1419.9 ± 5.118.2 ± 4.322.1 ± 3.0
0400 PM Day 1419.7 ± 5.218.0 ± 2.822.0 ± 3.9
0800 AM Day 2119.7 ± 3.619.2 ± 2.823.4 ± 3.9
1000 AM Day 2119.2 ± 5.019.1 ± 3.322.6 ± 3.2
0400 PM Day 2118.7 ± 5.218.8 ± 3.021.7 ± 3.7
SecondaryMean Change in Intraocular Pressure From Baseline

mmHg

Time frame:
8AM, 10AM, and 4PM at Day 7; Day 14 and Day 21
Reported as:
Mean · mmHg
Mean Change in Intraocular Pressure From Baseline
mmHgVVN539 Ophthalmic Solution 0.02%VVN539 Ophthalmic Solution 0.04%VVN539 Ophthalmic Solution Vehicle
0800 AM Day 7-3.6 ± 4.1-4.1 ± 2.7-2.0 ± 2.8
1000 AM Day 7-5.3 ± 4.2-5.0 ± 3.0-2.3 ± 3.0
0400 PM Day 7-3.3 ± 3.5-4.6 ± 2.6-1.3 ± 2.2
0800 AM Day 14-4.3 ± 4.3-5.0 ± 4.0-2.2 ± 2.7
1000 PM Day 14-5.1 ± 4.2-5.8 ± 3.6-2.1 ± 2.3
0400 PM Day 14-2.7 ± 4.6-4.8 ± 3.3-0.9 ± 3.5
0800 AM Day 21-5.7 ± 2.7-5.4 ± 2.8-2.0 ± 3.3
1000 AM Day 21-5.7 ± 3.9-5.0 ± 3.7-1.5 ± 2.4
0400 PM Day 21-3.7 ± 4.3-3.9 ± 2.8-1.2 ± 3.4

Adverse events

Collected over 21 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VVN539 Ophthalmic Solution 0.02%0/23 (0%)0/23 (0%)11/23 (47.8%)
VVN539 Ophthalmic Solution 0.04%0/22 (0%)0/22 (0%)10/22 (45.5%)
VVN539 Ophthalmic Solution Vehicle0/23 (0%)0/23 (0%)1/23 (4.3%)
Most frequent other events
Most frequent other events
EventVVN539 Ophthalmic Solution 0.02%VVN539 Ophthalmic Solution 0.04%VVN539 Ophthalmic Solution Vehicle
Conjunctival hyperaemiaEye disorders11/2310/221/23
Ocular hyperaemiaEye disorders3/235/220/23
Eye painEye disorders1/233/220/23
Eye irritationEye disorders1/232/220/23
Vision blurredEye disorders1/232/220/23

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)VVN539 Ophthalmic Solution 0.02%VVN539 Ophthalmic Solution 0.04%VVN539 Ophthalmic Solution VehicleTotal
<=18 years0000
Between 18 and 65 years59923
>=65 years18131445
Age, Continuous
Age, Continuous(years)VVN539 Ophthalmic Solution 0.02%VVN539 Ophthalmic Solution 0.04%VVN539 Ophthalmic Solution VehicleTotal
Mean69.1 ± 9.065.1 ± 13.464.7 ± 16.466.3 ± 13.2
Sex: Female, Male
Sex: Female, Male(Participants)VVN539 Ophthalmic Solution 0.02%VVN539 Ophthalmic Solution 0.04%VVN539 Ophthalmic Solution VehicleTotal
Female1291233
Male11131135
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VVN539 Ophthalmic Solution 0.02%VVN539 Ophthalmic Solution 0.04%VVN539 Ophthalmic Solution VehicleTotal
Hispanic or Latino62311
Not Hispanic or Latino17202057
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VVN539 Ophthalmic Solution 0.02%VVN539 Ophthalmic Solution 0.04%VVN539 Ophthalmic Solution VehicleTotal
American Indian or Alaska Native0000
Asian2002
Native Hawaiian or Other Pacific Islander0000
Black or African American1304
White18192360
More than one race0000
Unknown or Not Reported2002
Region of Enrollment
Region of Enrollment(participants)VVN539 Ophthalmic Solution 0.02%VVN539 Ophthalmic Solution 0.04%VVN539 Ophthalmic Solution VehicleTotal
United States23222368
08

Study locations

1 site
  • Lexitas
    Durham, North Carolina 27701, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Dec 2022, 5 months.

Results were first posted in Jan 2024, 1 year after primary completion.

Of 38 industry-sponsored phase 2 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 5 months is below that.

Counting every sponsor, half of 41 studies reached it within 11 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2022
First posted
Jul 11, 2022
StartActual
Jul 12, 2022
Primary completionActual
Dec 22, 2022
CompletionActual
Dec 22, 2022
Results first posted
Jan 17, 2024
Last update
Jan 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05451329
Lead sponsor
VivaVision Biotech, Inc
Responsible party
Sponsor
First posted
Jul 11, 2022
Start date
Jul 12, 2022
Primary completion
Dec 22, 2022
Completion
Dec 22, 2022
Results posted
Jan 17, 2024
Last update
Jan 17, 2024

Study contacts

Xiao-Yan Li, M.D.
study director · VivaVision

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion